InvestorsHub Logo
Followers 28
Posts 398
Boards Moderated 0
Alias Born 12/10/2015

Re: None

Wednesday, 09/19/2018 11:43:33 AM

Wednesday, September 19, 2018 11:43:33 AM

Post# of 458250
CTAD Late Breaker Oral Communications Update!

10/26, 3-3:45pm - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers

Harald Hampel, MD, PhD1, Mohammad Afshar, MD, PhD2, Frédéric Parmentier, PhD2, Coralie Williams, MSc2, Adrien Etcheto, MSc2, Federico Goodsaid, PhD3, Christopher U Missling, PhD4; 1Department of Neurology, Sorbonne University, Paris, France, 2Ariana Pharma, Paris, France, 3Regulatory Pathfinders LLC, San Francisco, CA, 4Anavex Life Sciences Corp., New York, NY

http://www.ctad-alzheimer.com/files/files/Late%20call%20for%20abstracts.docx.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News